News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Peplin Inc.’s Positive Phase IIb AK Trial Result Details


3/6/2009 12:41:07 PM

EMERYVILLE, Calif. & BRISBANE, Australia--(BUSINESS WIRE)--Peplin, Inc. (ASX:PLI) today announced further results of its Phase IIb actinic (solar) keratosis (AK) Australian and US trial for lesions on the head, which comprise face and scalp, and the selection of a Phase III dose for its lead product candidate PEP005 (ingenol mebutate) Gel.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES